This is in line with reports that a B-cell signature, when adjusted for IL-8 expression is prognostic in triple-negative breast cancers41, that a B-cell signature is associated with good prognosis particularly in cancers with high proliferation rate42 or in basal-like and HER2-enriched tumors43, and that the amount of B-lymphocytes is associated with improved prognosis particularly in grade 3 and ER-negative tumors7. This evidence concerns the gene ERBB2 and cancer.